Medulloblastoma in young children.
Standard
Medulloblastoma in young children. / Rutkowski, Stefan; Cohen, Bruce; Finlay, Jonathan; Luksch, Roberto; Ridola, Vita; Valteau-Couanet, Dominique; Hara, Junichi; Garre, Maria-Luisa; Grill, Jacques.
in: PEDIATR BLOOD CANCER, Jahrgang 54, Nr. 4, 4, 2010, S. 635-637.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Medulloblastoma in young children.
AU - Rutkowski, Stefan
AU - Cohen, Bruce
AU - Finlay, Jonathan
AU - Luksch, Roberto
AU - Ridola, Vita
AU - Valteau-Couanet, Dominique
AU - Hara, Junichi
AU - Garre, Maria-Luisa
AU - Grill, Jacques
PY - 2010
Y1 - 2010
N2 - In early childhood medulloblastoma, three distinct treatment strategies are currently used by different national groups to improve survival rates and to delay or avoid craniospinal radiotherapy: (1) systemic chemotherapy and high-dose chemotherapy, followed by radiotherapy at relapse; (2) systemic and intraventricular chemotherapy; (3) systemic chemotherapy and local conformal radiotherapy. A role for high-dose chemotherapy to delay or avoid craniospinal radiotherapy as a part of multimodal treatment strategies, especially in young children with metastatic or postoperative residual disease, has been recognized by different co-operative groups. Clinical and histological factors such as nodular-desmoplastic variants are considered as important prognostic factors for risk-adapted treatment recommendations.
AB - In early childhood medulloblastoma, three distinct treatment strategies are currently used by different national groups to improve survival rates and to delay or avoid craniospinal radiotherapy: (1) systemic chemotherapy and high-dose chemotherapy, followed by radiotherapy at relapse; (2) systemic and intraventricular chemotherapy; (3) systemic chemotherapy and local conformal radiotherapy. A role for high-dose chemotherapy to delay or avoid craniospinal radiotherapy as a part of multimodal treatment strategies, especially in young children with metastatic or postoperative residual disease, has been recognized by different co-operative groups. Clinical and histological factors such as nodular-desmoplastic variants are considered as important prognostic factors for risk-adapted treatment recommendations.
M3 - SCORING: Zeitschriftenaufsatz
VL - 54
SP - 635
EP - 637
JO - PEDIATR BLOOD CANCER
JF - PEDIATR BLOOD CANCER
SN - 1545-5009
IS - 4
M1 - 4
ER -
